^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Thyroid Gland Papillary Carcinoma |
| Drug: | Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma.
Excerpt:
Single agent dabrafenib, as well as combination of dabrafenib/trametinib are well tolerated therapies that result in similar high objective response rates with durable responses in pts with progressive BRAF-mutated PTC.
DOI:
10.1200/JCO.2017.35.15_suppl.6022
Trial ID:
